From Development to Commercial Success: Accelerate Your Biologics Programs

Barbara Fedejko-Kap is the Group Director of Analytical Development at Rezon Bio, where she leads the technical, strategic and operational planning of analytical development programs. Her focus lies in optimizing value, time, resources and risk across the biologics lifecycle.

With a strong academic foundation and over a decade of industry experience, Barbara combines scientific expertise with advanced analytical technologies to accelerate biologics development without compromising quality. She has contributed to all products developed at Polpharma Biologics, specializing in comparability studies, process and product control strategies, structure-function and impurity characterization, as well as method validation and technology transfer across sites.

Barbara holds a Ph.D. in Biotechnology from the Gdańsk University of Technology and is currently expanding her business expertise through participation in an Executive International MBA program, strengthening her leadership perspective and strategic insight within the life sciences industry.

Dawid Suwala is the Drug Substance Manufacturing Director at Rezon Bio, where he leads commercial GMP manufacturing and tech transfer operations across the company’s facilities in Poland. Over more than a decade, he has played an instrumental role in shaping the organization’s biomanufacturing capabilities, from its early development as Polpharma Biologics through its evolution into Rezon Bio.

With extensive expertise in upstream and downstream processing, Dawid has successfully overseen multiple technology transfers and GMP manufacturing programs under EMA and FDA oversight. His leadership combines scientific and operational depth with a focus on efficiency, quality, and team development.

Dawid is currently pursuing an Executive MBA at Mannheim Business School and ESSEC Business School and holds postgraduate qualifications in Production Management from AGH University of Krakow, blending technical excellence with a strong foundation in business and organizational leadership.

Felix Faupel is the Chief Business Officer at Rezon Bio, responsible for driving the company’s global commercial strategy and client partnerships. With more than a decade of experience across the biopharmaceutical and CDMO sectors, Felix brings a unique combination of scientific understanding and business acumen to help clients navigate the complexities of biologics development and manufacturing.

Felix joined the organization during its evolution from Polpharma Biologics to Rezon Bio, where he play a key role in shaping its CDMO strategy and market positioning. Prior to that, he held senior leadership roles in biopharmaceutical CDMOs, including Chief Commercial Officer at Bacthera. Throughout his career, he has built high-performing commercial teams, led major partnership agreements, and supported clients from early-stage development through commercial launch.

Felix holds an MSc and a BSc in Chemistry and Business Studies from the University of Zurich and is passionate about building collaborative, transparent relationships that create long-term value for clients and their patients.